Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 9,705,737
  • Shares Outstanding, K 60,090
  • Annual Sales, $ 1,488 M
  • Annual Income, $ 396,830 K
  • 36-Month Beta 1.11
  • Price/Sales 6.51
  • Price/Cash Flow 18.13
  • Price/Book 4.88

Price Performance

See More
Period Period Low Period High Performance
1-Month
151.88 +4.45%
on 07/13/17
162.59 -2.43%
on 07/26/17
+3.78 (+2.44%)
since 06/27/17
3-Month
144.91 +9.47%
on 06/06/17
163.75 -3.12%
on 04/28/17
-3.37 (-2.08%)
since 04/27/17
52-Week
95.80 +65.59%
on 11/04/16
163.75 -3.12%
on 04/28/17
+16.73 (+11.79%)
since 07/27/16

Most Recent Stories

More News
Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates

Jazz Pharmaceuticals plc today announced that it has entered into a license agreement with XL-protein GmbH ("XLp") for the rights to develop, manufacture and commercialize products using XLp's PASylation(R)...

JAZZ : 158.64 (-1.78%)
Jazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017

Jazz Pharmaceuticals plc today announced that it will report its 2017 second quarter financial results on Tuesday, August 8, 2017, after the close of the financial markets. Company management will host...

JAZZ : 158.64 (-1.78%)
AVEO's Kidney Cancer Candidate Gets CHMP Recommendation

AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment...

AVEO : 2.53 (+3.27%)
JAZZ : 158.64 (-1.78%)
EXEL : 27.11 (-3.25%)
BMY : 54.24 (-3.11%)
After Yesterday's Rally of 2.04% Shares Could Potentially Pullback

Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $152.02 to a high of $155.82. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day...

JAZZ : 158.64 (-1.78%)
Jazz Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.11%

Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $146.54 to a high of $149.76. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low...

JAZZ : 158.64 (-1.78%)
Why Is Jazz Pharmaceuticals (JAZZ) Down 3.3% Since the Last Earnings Report?

Jazz Pharmaceuticals (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

JAZZ : 158.64 (-1.78%)
SmarTrend Watching for Potential Pullback in Shares of Jazz Pharmaceuticals After 3.96% Gain

Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $146.10 to a high of $152.78. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day...

JAZZ : 158.64 (-1.78%)
Jazz Pharma Sleep Disorder Candidate Positive in Phase III

Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy results from studies evaluating its lead pipeline candidate, JZP-110, in adult patients with excessive sleepiness (ES) associated with narcolepsy...

JAZZ : 158.64 (-1.78%)
VVUS : 1.14 (-3.78%)
ZTS : 62.01 (-0.08%)
NVS : 84.97 (+0.14%)
Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea

Data were presented in a poster presentation at the annual SLEEP Meeting; JZP-110 U.S. NDA submission planned for later this year

JAZZ : 158.64 (-1.78%)
Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented positive efficacy results from its global multicenter studies (TONES 3 and TONES 4) of JZP-110 in adult patients with excessive sleepiness associated...

JAZZ : 158.64 (-1.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Support & Resistance

2nd Resistance Point 163.43
1st Resistance Point 162.47
Last Price 158.64
1st Support Level 160.68
2nd Support Level 159.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.